TNXP (Tonix Pharmaceuticals Holding) Scaled Net Operating Assets: 0.15 (As of Mar. 2026)


TNXP Tonix Pharmaceuticals Holding Corp TNXP
41 GF Score
Price $12.40
GF Value $1.75
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Tonix Pharmaceuticals Holding Scaled Net Operating Assets?

Tonix Pharmaceuticals Holding TNXP -2.75% 41 Scaled Net Operating Assets is 0.15 as of Mar. 2026. GuruFocus rates TNXP with a GF Score™ of 41/100 and a GF Value™ of $1.75 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Tonix Pharmaceuticals Holding's operating assets for the quarter that ended in Mar. 2026 was $72.44 Mil. Tonix Pharmaceuticals Holding's operating liabilities for the quarter that ended in Mar. 2026 was $29.49 Mil. Tonix Pharmaceuticals Holding's Total Assets for the quarter that ended in Dec. 2025 was $277.17 Mil. Therefore, Tonix Pharmaceuticals Holding's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.15.


Tonix Pharmaceuticals Holding Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Tonix Pharmaceuticals Holding's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tonix Pharmaceuticals Holding Scaled Net Operating Assets Chart

Tonix Pharmaceuticals Holding Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.42 0.36 0.40 0.32 0.24

Tonix Pharmaceuticals Holding Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.30 0.22 0.22 0.15 0.16

TNXP vs ALEC, IMUX, WHWK: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Tonix Pharmaceuticals Holding's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tonix Pharmaceuticals Holding Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tonix Pharmaceuticals Holding's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Tonix Pharmaceuticals Holding's Scaled Net Operating Assets falls into.


TNXP
41GF Score
Tonix Pharmaceuticals Holding Corp TNXP
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tonix Pharmaceuticals Holding Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Tonix Pharmaceuticals Holding's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2025 )
=(Operating Assets (A: Dec. 2025 )-Operating Liabilities (A: Dec. 2025 ))/Total Assets (A: Dec. 2024 )
=(69.534-30.712)/162.89
=0.24

where

Operating Assets(A: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=277.171 - 207.637
=69.534

Operating Liabilities(A: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=32.021 - 1.184 - 0.125
=30.712

Tonix Pharmaceuticals Holding's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2026 )
=(Operating Assets (Q: Mar. 2026 )-Operating Liabilities (Q: Mar. 2026 ))/Total Assets (Q: Dec. 2025 )
=(72.442-29.485)/277.171
=0.15

where

Operating Assets(Q: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=257.912 - 185.47
=72.442

Operating Liabilities(Q: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=30.775 - 1.128 - 0.162
=29.485

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.15 mean?
Tonix Pharmaceuticals Holding (TNXP) has a Scaled Net Operating Assets of 0.15 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Tonix Pharmaceuticals Holding and its competitors.
Is Tonix Pharmaceuticals Holding's Scaled Net Operating Assets too high?
Tonix Pharmaceuticals Holding's current Scaled Net Operating Assets is 0.15. Overall, Tonix Pharmaceuticals Holding has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tonix Pharmaceuticals Holding's Scaled Net Operating Assets compare to ALEC and IMUX?
Tonix Pharmaceuticals Holding's Scaled Net Operating Assets of 0.15 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Tonix Pharmaceuticals Holding and its competitors. Tonix Pharmaceuticals Holding's current Scaled Net Operating Assets is 0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tonix Pharmaceuticals Holding stock overvalued right now?
Based on GuruFocus' analysis, Tonix Pharmaceuticals Holding (TNXP) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.75, compared to a current price of $12.40 — trading 608.6% above its estimated fair value. The current Scaled Net Operating Assets is 0.15. Tonix Pharmaceuticals Holding's overall GF Score™ is 41/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Tonix Pharmaceuticals Holding (TNXP), the current Scaled Net Operating Assets is 0.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tonix Pharmaceuticals Holding (TNXP) Overvalued in 2026?

Based on GuruFocus' analysis, Tonix Pharmaceuticals Holding stock appears to be overvalued. The current stock price of $12.40 is trading 608.6% above its estimated GF Value™ of $1.75. GuruFocus considers Tonix Pharmaceuticals Holding to be Significantly Overvalued.

Key valuation signals for TNXP:

  • Scaled Net Operating Assets: 0.15
  • GF Value™: $1.75 vs. price of $12.40 (608.6% above fair value)
  • GF Score™: 41/100 with 2 warning signs

No single metric tells the full story. See the TNXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tonix Pharmaceuticals Holding Business Description

Other Exchanges TPM0:Germany
Address 200 Connell Drive, Suite 3100, Berkeley Heights, NJ, USA, 07928
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
41GF Score

Get the complete analysis for TNXP

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.40
Price
$1.75
GF Value